NSCLC

This early-phase trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors (like breast, ovarian, lung, and pancreatic cancers) that have no curative options. The main goal is to find safe doses and under…

This early-phase study tests whether combining low-dose radiation with targeted radiation (SBRT) and an immunotherapy drug (PD-1 inhibitor) is safe for people with advanced non-small cell lung cancer who have not responded to standard treatments. Nine participants will receive th…

This early-stage study tests a drug called furmonertinib in 30 people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). Some participants have already tried other treatments, while others are new to therapy. The goal is to see how wel…

This study tests a new drug, cadonilimab, combined with standard chemotherapy and radiation for people with stage III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination helps shrink tumors and control the disease. 41 adults who ha…

This study looks at whether a blood test (liquid biopsy) can help doctors see how well the drug brigatinib is working in people with a specific type of advanced lung cancer (ALK-positive NSCLC). About 33 patients will take brigatinib pills and give blood samples over time. The go…

This study looks at whether giving the drug serplulimab together with chemotherapy before surgery can help people with a certain type of lung cancer (non-small cell lung cancer). The goal is to shrink tumors and make surgery more effective, possibly reducing the chance of cancer …

This study offers continued access to the drug crizotinib for people with certain cancers (NSCLC, ALCL, IMT) who are already benefiting from it in a previous Pfizer study that is ending. The main goal is to track long-term safety, not to test if the drug works. About 27 participa…

This study tests whether adding the drug durvalumab to precise radiation therapy (SBRT) can keep early-stage non-small cell lung cancer from coming back longer than radiation alone. It involves 13 adults with stage I to IIIA disease. The main goal is to see how long participants …

This study tests a daily pill called lazertinib in 150 people with advanced non-small cell lung cancer that has specific EGFR mutations. The goal is to see how long the drug can control the cancer and how safe it is. Participants have not had prior targeted therapy for their canc…

This study tests whether combining the drug durvalumab with radiation therapy can slow down cancer growth in people with locally advanced non-small cell lung cancer. About 61 adults with stage II or III lung cancer who would normally receive chemotherapy followed by radiation are…

This study looks at whether giving precise radiation to tumors that have just started to grow again can help people with metastatic breast or lung cancer live longer without their disease getting worse. About 107 adults with triple-negative breast cancer or certain types of lung …

This study tests an experimental oral drug, MRT-2359, in people with certain advanced cancers, including lung cancer and lymphoma, that are driven by MYC genes. The trial has two phases: first, finding a safe dose, and second, checking if the drug shrinks tumors. About 174 adults…

This study tests new treatments for non-small cell lung cancer given before surgery. The goal is to see if these treatments shrink tumors and make surgery more effective. About 4 adults with early-stage lung cancer that can be removed surgically are taking part. The main focus is…

This early-phase study tests a new drug, BG-60366, designed to break down a faulty protein (mutant EGFR) that drives non-small cell lung cancer. About 33 adults with advanced or spreading lung cancer who have already tried other treatments will receive the drug to see if it is sa…

This study looks at whether it is safe to continue the targeted therapy osimertinib while also giving radiation to people with advanced EGFR-positive non-small cell lung cancer. The goal is to manage cancer that has started to grow in a few new spots. Researchers will track side …

This study tests an experimental drug called JAB-21822 (glecirasib) in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and can shrink tumors. About 315 adults whose cancer has not responded to standard treatments w…

This study tests a daily pill called furmonertinib in about 100 people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). Participants must have already tried platinum chemotherapy. The goal is to see if the drug shrinks tumors and how…

This study tests a new pill, poziotinib, against standard chemotherapy (docetaxel) in people with advanced lung cancer that has a specific genetic change (HER2 mutation). The goal is to see if poziotinib can keep tumors from growing longer than chemo. About 268 adults who have al…

This phase 2 trial studies the best strategy for giving the drug osimertinib to people with advanced EGFR-mutant non-small cell lung cancer. It compares starting osimertinib right away versus using it after another drug stops working. The study also checks if blood tests (liquid …

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy after lung cancer surgery can clear tiny bits of tumor DNA from the blood. About 100 adults with early-stage non-small cell lung cancer who had surgery and still have detectable tumor DNA…

This study tests whether adding a special type of radiotherapy to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with stage III lung cancer that has spread to lymph nodes. About 90 participants will receive one of three radiation schedules …

This study tests giving chemotherapy plus the immunotherapy drug nivolumab before surgery to people with a rare lung cancer called Pancoast tumor. The goal is to see if this combination helps shrink the tumor enough for complete removal and improves survival. About 22 adults with…

This study offers continued treatment with avelumab to cancer patients who are already benefiting from it in earlier Pfizer studies. It includes safety monitoring and survival follow-up for people with advanced cancers like lung, ovarian, and bladder cancer. The goal is to keep p…

This study tests a new drug called AK112 combined with chemotherapy in 265 adults with advanced non-small cell lung cancer (NSCLC) that has spread. The goal is to see if the combo can shrink tumors and delay cancer growth. Participants must have stage IIIB/C or IV NSCLC and be in…

This early-stage study tests a new drug called CLN-619, given alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors. About 440 peopl…

This study tests a new drug called LP-184 in people with advanced solid tumors (like certain breast, lung, or pancreatic cancers) that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 64 participan…

This study looks at whether adding high-dose vitamin C (ascorbate) to the usual treatment of radiation and chemotherapy can help people with non-small cell lung cancer. About 43 participants will receive the vitamin C alongside their standard therapy. The goal is to see if this c…

This study tests whether adding a chemotherapy drug called S-1 to the targeted therapy osimertinib can shrink tumors in people with a specific type of lung cancer (EGFR mutant NSCLC) that has stopped responding to treatment. About 30 adults with advanced lung cancer will receive …

This study looks at using radiofrequency ablation (RFA), a treatment that uses heat to destroy tumors, for people with lung cancer or tumors that have spread to the lungs. It includes 72 patients who cannot have surgery due to other health issues or who choose not to. The goal is…

This study tests an experimental pill called BDTX-1535 for people with advanced non-small cell lung cancer or a type of brain tumor called glioblastoma that have certain genetic changes. The goal is to find the best dose and see if the drug can shrink tumors or slow their growth.…

This study offers continued treatment with lorlatinib for people with ALK-positive or ROS1-positive non-small cell lung cancer who are already benefiting from it in earlier Pfizer studies. The main goal is to monitor long-term safety and side effects. About 76 participants will t…

This early-stage study tests a new drug called TT125-802 in about 50 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also watch for signs that the drug sh…

This study tests a new combination of drugs (datopotamab deruxtecan, durvalumab, and carboplatin) against the current standard treatment for advanced non-small cell lung cancer (NSCLC) that has not spread to the brain or bones. About 1,350 adults with stage IIIB, IIIC, or IV NSCL…

This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers, including solid tumors, lymphoma, lung cancer, melanoma, and myelofibrosis. The main goal is to check if the drug is safe and tolerable, and to see if it can boost the …

This study tests whether adding an experimental immunotherapy drug (tiragolumab) to standard immunotherapy (atezolizumab) plus chemoradiation helps people with stage III lung cancer live longer without the disease getting worse. About 178 participants will receive either the two-…

This study tests the drug brigatinib in 118 adults with advanced ALK-positive non-small cell lung cancer. The goal is to see how long the drug can keep the cancer from growing. Participants take brigatinib as their first treatment, and researchers track tumor progression and side…

This early-phase trial tests a combination of two experimental drugs, defactinib and VS-6766, in people with advanced solid tumors that have not responded to standard treatments. The study includes patients with certain lung, ovarian, pancreatic, and endometrial cancers. The main…

This study looks at whether a blood test can find gene changes in lung cancer and melanoma tumors, instead of using a tissue biopsy. The test checks for specific mutations (EGFR, KRAS, BRAF) that help doctors choose the right targeted therapy. About 840 people with these cancers …

This study looks at two ways to give radiation to people with cancer that has spread to the brain. All participants are also receiving immunotherapy. The standard approach gives a single high dose of radiation, while the experimental approach gives a lower dose over a few days. T…

This study aims to understand why some people under 50 develop lung cancer by looking at their lifestyle, environment, and genetics. Participants complete online surveys and may donate blood. The goal is to find patterns that could help prevent or catch the disease earlier.

This study observes how doctors manage and treat people with ALK-positive advanced non-small cell lung cancer who are taking the drug alectinib in everyday practice. Researchers will track outcomes like how long the cancer stays under control and overall survival. The study does …

This study looks at whether a simple blood test (called MiTest) can find tiny bits of cancer DNA left behind after lung cancer surgery. Researchers will follow 133 people with stage I to IIIA lung cancer for one year to see if the test results match who stays cancer-free. The goa…

This study tracks 330 people with non-small cell lung cancer who receive immunotherapy before surgery. Researchers measure cortisol (a stress hormone) at different times to see if changes relate to how well the treatment works. The goal is to learn if cortisol levels can help pre…